Literature DB >> 105058

Neutralizing and hemagglutination-inhibiting antibodies to rubella virus as indicators of protective immunity in vaccinees and naturally immune individuals.

A Schluederberg, D M Horstmann, W A Andiman, M F Randolph.   

Abstract

In general, hemagglutination-inhibiting (HAI) and neutralizing (NT) antibodies to rubella virus tend to parallel one another, and the presence of either antibody has been interpreted as reflecting protective immunity. It has recently been shown that persons who have HAI antibody but lack NT antibody may be subject to reinfection. In the present study these two antibodies were compared with regard to their appearance and persistence in vaccines and in those who have experienced natural infection. NT antibody appeared more slowly following immunization with HPV77DE5 or Cendehill vaccines than after natural infection or immunization with RA 27/3 vaccine. As with natural infection, initial NT antibody responses to RA 27/3 vaccine were of higher titer and persisted at higher levels for three years than was the case with either of the other vaccines. NT testing procedures were found to differ in sensitivity, depending on several factors including the cells in which the virus was grown.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 105058     DOI: 10.1093/infdis/138.6.877

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Monoclonal antibodies directed to E1 glycoprotein of rubella virus.

Authors:  Y Umino; T A Sato; S Katow; T Matsuno; A Sugiura
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

2.  Comparison of the latex agglutination test with the hemagglutination inhibition test, enzyme-linked immunosorbent assay, and neutralization test for detection of antibodies to rubella virus.

Authors:  J M Meegan; B K Evans; D M Horstmann
Journal:  J Clin Microbiol       Date:  1982-10       Impact factor: 5.948

Review 3.  Rubella vaccination.

Authors:  J Forster
Journal:  Eur J Pediatr       Date:  1988-08       Impact factor: 3.183

4.  Rubella reimmunization: comparative analysis of the immunoglobulin G response to rubella virus vaccine in previously seronegative and seropositive individuals.

Authors:  L A Mitchell; M K Ho; J E Rogers; A J Tingle; R G Marusyk; J M Weber; P Duclos; M L Tepper; M Lacroix; M Zrein
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

5.  Placental transfer of maternal rubella antibodies to full-term and preterm infants.

Authors:  N Linder; L Sirota; Y Aboudy; B German; T Lifshits; B S Barnea; B Lieberman; E Mendelson; A Barzilai
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

6.  Rubella immunization of teenage girls in Iceland and follow-up after a severe rubella epidemic.

Authors:  B Rafnar
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

7.  Use of enzyme immunoassays and the latex agglutination test to measure the temporal appearance of immunoglobulin G and M antibodies after natural infection or immunization with rubella virus.

Authors:  J M Meegan; B K Evans; D M Horstmann
Journal:  J Clin Microbiol       Date:  1983-09       Impact factor: 5.948

8.  Immune responses to wild and vaccine rubella viruses after rubella vaccination.

Authors:  M G Cusi; R Metelli; P E Valensin
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

9.  Comparison of several test systems used for determination of rubella immune status.

Authors:  A S Weissfeld; W D Gehle; A C Sonnenwirth
Journal:  J Clin Microbiol       Date:  1982-07       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.